Skip to content
2000
Volume 28, Issue 9
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

Background

Various cancer types have been studied and understood using long noncoding RNA (lncRNA). Despite this, only a few studies have examined anoikis-related lncRNAs in kidney renal clear cell carcinoma (KIRC). As a result, this study evaluated a powerful prognostic model for KIRC patients based on anoikis-lncRNAs and identified potential biological targets.

Methods

Anoikis-related lncRNAs associated with patient prognosis were identified using Pearson correlation, variance, and univariate Cox regression analyses. A predictive model that incorporated 4 anoikis-related lncRNAs has been constructed using the least absolute shrinkage and selection operator (LASSO) regression algorithm. The prognostic performance of the proposed model has also been assessed utilizing Kaplan-Meier (KM) survival and receiver operating characteristic (ROC) curve analyses. An ESTIMATE analysis was carried out on the low- as well as high-risk subtypes to evaluate immune cell infiltration status. Furthermore, CIBERSORT, TIMER, and QUANTISEQ along with other algorithms were applied for determining the infiltration status of numerous immune cells across both groups. In addition, immune checkpoint gene expression in both groups was also determined. Finally, drug sensitivity assays and experiments were performed to validate the results.

Results

A total of sixty-three lncRNAs associated with anoikis and KIRC prognosis were identified univariate cox analysis, and four lncRNAs (Z99289.2, AC084876.1, LINC00460, and AC090337.2.) were selected as hub lncRNAs. A prognostic signature has been developed based on the expression levels and coefficiency of these four lncRNAs while establishing its efficacy in part and whole TCGA KIRC cohort. Furthermore, by using this risk signature, high- as well as low-risk KIRC patients could be distinguished more precisely it can predict patient outcomes as well. The survival predictions by the nomogram exhibited an absolute degree of concordance with actual situations. experiments verified that LINC00460 downregulation contributed to the growth inhibition of KIRC cell lines and promoted apoptosis of cancer cells.

Conclusion

This study suggests that anoikis-related lncRNAs could serve as valuable prognostic markers for KIRC. Additionally, they may provide insight into future KIRC treatment options by reflecting on the situation of the kidney immune microenvironment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073271880231114100544
2024-01-04
2025-09-05

  • From This Site

    /content/journals/cchts/10.2174/0113862073271880231114100544
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KlümperN. RalserD.J. BawdenE.G. LandsbergJ. ZarblR. KristiansenG. TomaM. RitterM. HölzelM. EllingerJ. DietrichD. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma.J. Immunother. Cancer202081e00055210.1136/jitc‑2020‑000552 32234847
     [Google Scholar]
  2. SiegelR.L. MillerK.D. FuchsH.E. JemalA. Cancer statistics, 2021.CA Cancer J. Clin.202171173310.3322/caac.21654 33433946
     [Google Scholar]
  3. KotechaR.R. MotzerR.J. VossM.H. Towards individualized therapy for metastatic renal cell carcinoma.Nat. Rev. Clin. Oncol.2019161062163310.1038/s41571‑019‑0209‑1 30992569
     [Google Scholar]
  4. HuangY. WangJ. JiaP. LiX. PeiG. WangC. FangX. ZhaoZ. CaiZ. YiX. WuS. ZhangB. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.Nat. Commun.2019101124510.1038/s41467‑019‑09241‑7 30886153
     [Google Scholar]
  5. LiuW. RenD. XiongW. JinX. ZhuL. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.J. Exp. Clin. Cancer Res.20224113810.1186/s13046‑022‑02253‑0 35081978
     [Google Scholar]
  6. WeiJ.H. FengZ.H. CaoY. ZhaoH.W. ChenZ.H. LiaoB. WangQ. HanH. ZhangJ. XuY.Z. LiB. WuJ.T. QuG.M. WangG.P. LiuC. XueW. LiuQ. LuJ. LiC.X. LiP.X. ZhangZ.L. YaoH.H. PanY.H. ChenW.F. XieD. ShiL. GaoZ.L. HuangY.R. ZhouF.J. WangS.G. LiuZ.P. ChenW. LuoJ.H. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma:] A retrospective analysis and multicentre validation study.Lancet Oncol.201920459160010.1016/S1470‑2045(18)30932‑X 30880070
     [Google Scholar]
  7. FlorosT. TarhiniA.A. Anticancer Cytokines: Biology and clinical effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.Semin. Oncol.201542453954810.1053/j.seminoncol.2015.05.015 26320059
     [Google Scholar]
  8. O’BrienM.F. ReaD. RogersE. BredinH. ButlerM. GraingerR. McDermottT.E.D. MullinsG. O’BrienA. TwomeyA. ThornhillJ. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: The all Ireland experience.Eur. Urol.200445561361910.1016/j.eururo.2003.11.002 15082204
     [Google Scholar]
  9. KrownS.E. Interferon treatment of renal cell carcinoma. Current status and future prospects.Cancer198759S3Suppl.64765110.1002/1097‑0142(19870201)59:3+<647:AID‑CNCR2820591313>3.0.CO;2‑# 10822464
     [Google Scholar]
  10. NoessnerE. BrechD. MendlerA.N. MasourisI. SchlenkerR. PrinzP.U. Intratumoral alterations of dendritic-cell differentiation and CD8+ T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma.OncoImmunology2012181451145310.4161/onci.21356 23243626
     [Google Scholar]
  11. ChoueiriT.K. MotzerR.J. Systemic therapy for metastatic renal-cell carcinoma.N. Engl. J. Med.2017376435436610.1056/NEJMra1601333 28121507
     [Google Scholar]
  12. MotzerR.J. EscudierB. McDermottD.F. GeorgeS. HammersH.J. SrinivasS. TykodiS.S. SosmanJ.A. ProcopioG. PlimackE.R. CastellanoD. ChoueiriT.K. GurneyH. DonskovF. BonoP. WagstaffJ. GaulerT.C. UedaT. TomitaY. SchutzF.A. KollmannsbergerC. LarkinJ. RavaudA. SimonJ.S. XuL.A. WaxmanI.M. SharmaP. Nivolumab versus Everolimus in advanced renal-cell carcinoma.N. Engl. J. Med.2015373191803181310.1056/NEJMoa1510665 26406148
     [Google Scholar]
  13. KimJ.M. ChenD.S. Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure).Ann. Oncol.20162781492150410.1093/annonc/mdw217 27207108
     [Google Scholar]
  14. SchneiderB.J. NaidooJ. SantomassoB.D. LacchettiC. AdkinsS. AnadkatM. AtkinsM.B. BrassilK.J. CaterinoJ.M. ChauI. DaviesM.J. ErnstoffM.S. FecherL. GhoshM. JaiyesimiI. MammenJ.S. NaingA. NastoupilL.J. PhillipsT. PorterL.D. ReichnerC.A. SeigelC. SongJ.M. SpiraA. Suarez-AlmazorM. SwamiU. ThompsonJ.A. VikasP. WangY. WeberJ.S. FunchainP. BollinK. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.J. Clin. Oncol.202139364073412610.1200/JCO.21.01440 34724392
     [Google Scholar]
  15. OverholtzerM. MailleuxA.A. MouneimneG. NormandG. SchnittS.J. KingR.W. CibasE.S. BruggeJ.S. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion.Cell2007131596697910.1016/j.cell.2007.10.040 18045538
     [Google Scholar]
  16. FrischS.M. FrancisH. Disruption of epithelial cell-matrix interactions induces apoptosis.J. Cell Biol.1994124461962610.1083/jcb.124.4.619 8106557
     [Google Scholar]
  17. WatanabeJ. KushihataF. HondaK. SugitaA. TateishiN. MominokiK. MatsudaS. KobayashiN. Prognostic significance of Bcl-xL in human hepatocellular carcinoma.Surgery2004135660461210.1016/j.surg.2003.11.015 15179366
     [Google Scholar]
  18. SuX. ZhengX. NiJ. Lanthanum citrate induces anoikis of Hela cells.Cancer Lett.2009285220020910.1016/j.canlet.2009.05.018 19679391
     [Google Scholar]
  19. AokiM. KanamoriM. OhmoriK. TakaishiM. HuhN. NogamiS. KimuraT. Expression of developmentally regulated endothelial cell locus 1 was induced by tumor-derived factors including VEGF.Biochem. Biophys. Res. Commun.2005333399099510.1016/j.bbrc.2005.06.009 15964546
     [Google Scholar]
  20. RennebeckG. MartelliM. KyprianouN. Anoikis and survival connections in the tumor microenvironment: Is there a role in prostate cancer metastasis?Cancer Res.20056524112301123510.1158/0008‑5472.CAN‑05‑2763 16357123
     [Google Scholar]
  21. LeeH.Y. SonS.W. MoengS. ChoiS.Y. ParkJ.K. The role of noncoding RNAs in the regulation of Anoikis and Anchorage-independent growth in cancer.Int. J. Mol. Sci.202122262710.3390/ijms22020627 33435156
     [Google Scholar]
  22. LiottaL.A. KohnE. Cancer and the homeless cell.Nature2004430700397397410.1038/430973a 15329701
     [Google Scholar]
  23. PlyushchenkoI.V. FedorovaE.S. PotoldykovaN.V. PolyakovskiyK.A. GlukhovA.I. RodinI.A. Omics Untargeted Key Script: R-based software toolbox for untargeted metabolomics with bladder cancer biomarkers discovery case study.J. Proteome Res.202221383384710.1021/acs.jproteome.1c00392 34161108
     [Google Scholar]
  24. SimonN. FriedmanJ. HastieT. TibshiraniR. Regularization paths for Cox’s proportional hazards model via coordinate descent.J. Stat. Softw.201139511310.18637/jss.v039.i05 27065756
     [Google Scholar]
  25. OjedaF.M. MüllerC. BörnigenD. TrégouëtD.A. SchillertA. HeinigM. ZellerT. SchnabelR.B. Comparison of Cox model methods in a low-dimensional setting with few events.Genom Proteom Bioinformat201614423524310.1016/j.gpb.2016.03.006 27224515
     [Google Scholar]
  26. FerlayJ. SoerjomataramI. DikshitR. EserS. MathersC. RebeloM. ParkinD.M. FormanD. BrayF. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.Int. J. Cancer20151365E359E38610.1002/ijc.29210 25220842
     [Google Scholar]
  27. KumarR. KapoorA. Current management of metastatic renal cell carcinoma: Evolving new therapies.Curr. Opin. Support. Palliat. Care201711323123710.1097/SPC.0000000000000277 28590313
     [Google Scholar]
  28. ChowdhuryS. MatranaM.R. TsangC. AtkinsonB. ChoueiriT.K. TannirN.M. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: Recent progress and future directions.Hematol. Oncol. Clin. North Am.201125485386910.1016/j.hoc.2011.05.003 21763971
     [Google Scholar]
  29. MotzerR.J. PenkovK. HaanenJ. RiniB. AlbigesL. CampbellM.T. VenugopalB. KollmannsbergerC. NegrierS. UemuraM. LeeJ.L. VasilievA. MillerW.H.Jr GurneyH. SchmidingerM. LarkinJ. AtkinsM.B. BedkeJ. AlekseevB. WangJ. MarianiM. RobbinsP.B. ChudnovskyA. FowstC. HariharanS. HuangB. di PietroA. ChoueiriT.K. Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma.N. Engl. J. Med.2019380121103111510.1056/NEJMoa1816047 30779531
     [Google Scholar]
  30. McDermottD.F. HuseniM.A. AtkinsM.B. MotzerR.J. RiniB.I. EscudierB. FongL. JosephR.W. PalS.K. ReevesJ.A. SznolM. HainsworthJ. RathmellW.K. StadlerW.M. HutsonT. GoreM.E. RavaudA. BracardaS. SuárezC. DanielliR. GruenwaldV. ChoueiriT.K. NicklesD. JhunjhunwalaS. Piault-LouisE. ThobhaniA. QiuJ. ChenD.S. HegdeP.S. SchiffC. FineG.D. PowlesT. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Nat. Med.201824674975710.1038/s41591‑018‑0053‑3 29867230
     [Google Scholar]
  31. KakavandiE. ShahbahramiR. GoudarziH. EslamiG. FaghihlooE. Anoikis resistance and oncoviruses.J. Cell. Biochem.201811932484249110.1002/jcb.26363 28836703
     [Google Scholar]
  32. WeiL. YangY. YuQ. Tyrosine kinase-dependent, phosphatidylinositol 3′-kinase, and mitogen-activated protein kinase-independent signaling pathways prevent lung adenocarcinoma cells from anoikis.Cancer Res.200161624392444 11289112
     [Google Scholar]
  33. GrossmannJ. Molecular mechanisms of “detachment-induced apoptosis--Anoikis”.Apoptosis20027324726010.1023/A:1015312119693 11997669
     [Google Scholar]
  34. WangG. LiuP. LiJ. JinK. ZhengX. XieL. Novel prognosis and therapeutic response model of immune-related lncRNA pairs in clear cell renal cell carcinoma.Vaccines2022107116110.3390/vaccines10071161 35891325
     [Google Scholar]
  35. CaoH. TongH. ZhuJ. XieC. QinZ. LiT. LiuX. HeW. A glycolysis-based long non-coding RNA signature accurately predicts prognosis in renal carcinoma patients.Front. Genet.20211263898010.3389/fgene.2021.638980 33868376
     [Google Scholar]
  36. WangF. LiangS. LiuX. HanL. WangJ. DuQ. LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer.OncoTargets Ther.2018116383639410.2147/OTT.S169307 30323616
     [Google Scholar]
  37. ZhangS. XuJ. WangH. GuoH. Downregulation of long noncoding RNA LINC00460 expression suppresses tumor growth in vitro and in vivo in gastric cancer.Cancer Biomark.201924442943710.3233/CBM‑182177 30909185
     [Google Scholar]
  38. XueK. LiJ. NanS. ZhaoX. XuC. Downregulation of LINC00460 decreases STC2 and promotes autophagy of head and neck squamous cell carcinoma by up-regulating microRNA-206.Life Sci.201923111645910.1016/j.lfs.2019.05.015 31075234
     [Google Scholar]
  39. SunZ. ZhaoY. WeiY. DingX. TanC. WangC. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.Front. Immunol.20221393952310.3389/fimmu.2022.939523 36091049
     [Google Scholar]
  40. FuJ.H. ZhouC.C. MuH.Q. NanC.J. LiS. LuD.Q. CD18 inhibits progression of kidney cancer by down-regulating Treg cell levels.Eur. Rev. Med. Pharmacol. Sci.20192372750275510.26355/eurrev_201904_17548 31002125
     [Google Scholar]
  41. DannenmannS.R. ThielickeJ. StöckliM. MatterC. von BoehmerL. CecconiV. HermannsT. HefermehlL. SchramlP. MochH. KnuthA. van den BroekM. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma.OncoImmunology201323e2356210.4161/onci.23562 23687622
     [Google Scholar]
  42. ZhangW. ZhuX.D. SunH.C. XiongY.Q. ZhuangP.Y. XuH.X. KongL.Q. WangL. WuW.Z. TangZ.Y. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.Clin. Cancer Res.201016133420343010.1158/1078‑0432.CCR‑09‑2904 20570927
     [Google Scholar]
  43. AggenD.H. DrakeC.G. RiniB.I. Targeting PD-1 or PD-L1 in metastatic kidney cancer: Combination therapy in the first-line setting.Clin. Cancer Res.20202692087209510.1158/1078‑0432.CCR‑19‑3323 31948999
     [Google Scholar]
/content/journals/cchts/10.2174/0113862073271880231114100544
Loading
Development and Validation of Anoiki-Related Lncrna Signature Prediction Model for KIRC Prognosis
Comb Chem High Throughput Screen 28, 1524 (2025); https://doi.org/10.2174/0113862073271880231114100544
/content/journals/cchts/10.2174/0113862073271880231114100544
/content/journals/cchts/10.2174/0113862073271880231114100544
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Anoikis; kidney renal clear cell carcinoma (KIRC); lncRNA; prognostic signature (PS); the least absolute shrinkage and selection operator

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test